Eli Lilly Plunges 12.91% on Trump's 250% Tariff Threat

On August 7, 2025, Eli Lilly's stock experienced a significant drop of 12.91% in pre-market trading.

President Donald Trump's announcement of a potential 250% tariff on pharmaceutical imports has sent shockwaves through the industry, with Eli Lilly's stock price taking a notable hit. This move by the Trump administration has raised concerns about the financial impact on pharmaceutical companies, including Eli Lilly, which relies heavily on international trade.

Eli Lilly's recent clinical trial results for its oral GLP-1 drug, orforglipron, have shown promising weight loss outcomes, with an average loss of 27.3 pounds in the first of two pivotal Phase 3 trials. However, the stock's performance has been overshadowed by the tariff threat, which has overshadowed the positive news from the clinical trials.

Despite the recent setbacks, Eli Lilly continues to focus on its core strengths in diabetes, oncology, immunology, and neuroscience. The company's ongoing research and development efforts are expected to drive future growth, although the current market volatility poses a challenge.